オプションチェーンは、Slide Insurance Holdingsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Slide Insurance Holdingsの市場センチメントを評価します。.

Slide Insurance Holdings (NASDAQ:SLDE) 株価情報, オプションチェーン

Slide Insurance Holdings Inc is a technology enabled coastal specialty insurer. It is focus on profitable underwriting of single family, condominium and commercial residential policies in the P&C industry in coastal states along the Atlantic seaboard through insurance subsidiary, Slide Insurance Company (SIC). The Company has one reportable segment: insurance.

Slide Insurance Holdings, Inc. - Common Stock

Slide Insurance Holdings Inc

Telsey Advisory Group analyst Dana Telsey maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Outperform and maintains $520 price target.

News

Price Target

Analyst Ratings

ULTA

Telsey Advisory Group Maintains Outperform on Ulta Beauty, Maintains $520 Price Target

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) with a Buy and maintains $5 price target.

HOTH

D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target

Bernstein analysts have raised their price target for Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) to $510, citing accelerating growth in the company's derivatives business and <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">non-trading revenue streams</a>.
The updated price target marks a significant jump from the previous $310 target, reflecting Bernstein's increased confidence in Coinbase's evolving position as a leading crypto financial services platform.
Bernstein now values Coinbase at a price-to-earnings multiple of 25x based on 2027E earnings, up from its previous estimate of 21x on 2026 earnings, aligning the crypto exchange's valuation with its fintech and broker peers.
The brokerage house highlighted several drivers behind the target upgrade, including faster-than-expected revenue growth in non-trading businesses such as staking, stablecoins, and the company&#8217;s Base blockchain. 
The report also pointed to Coinbase's growing derivatives volumes, particularly in perpetual futures, which have shown a substantial increase in recent quarters.
Bernstein's revised model now forecasts Coinbase's total revenue to reach approximately $14.1 billion by 2027, up from the earlier estimate of $12.4 billion. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46095358/can-ledgers-mev-max-vault-boost-your-eth-rewards-what-crypto-stakers-need-to-know">Can Ledger&#8217;s MEV Max Vault Boost Your ETH Rewards? What Crypto Stakers Need To Know</a>
The firm's adjusted earnings per share estimate for 2027 has been lifted to $20.38, reflecting higher operating leverage.
&#8220;Operating leverage drives net income growth for Coinbase,&#8221; the report noted, supporting the thesis for an increased valuation.
Despite regulatory headwinds in past years, Bernstein sees Coinbase's market leadership as strengthening, particularly after the withdrawal of enforcement actions by U.S. regulators. 
The report emphasized Coinbase's dominant role in the U.S. spot crypto trading market and its expanding institutional business.
The analysts further noted that Coinbase&#8217;s share of perpetual futures volume climbed from 2.4% to 4.0% between Q4 FY24 and Q1 FY25, while the ratio of perpetual futures to spot trading volumes on its platform grew from 0.2 to 1.9 over the same period.
Bernstein described Coinbase as the "Amazon of crypto financial services," underscoring the company's integrated offerings across trading, custody, financing and staking.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46093380/as-bing-goes-private-presearch-opens-censorship-resistant-search-api-for-developers">As Bing Goes Private, Presearch Opens Censorship-Resistant Search API For Developers</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

COIN

Coinbase Is The 'Amazon Of Crypto Services', Price Target Boosted To $510: Bernstein

PDYN

Mobilicom And Palladyne AI Unveil Bundled Cybersecurity And AI Autonomy Solution For Secure, Autonomous Operations In Drones And Robotics

XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRTX#NASDAQ">XRTX</a>, TSXV:<a class="ticker" href="https://www.benzinga.com/stock/XRTX#TSXV">XRTX</a>, Frankfurt: ANU))), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces a non-brokered private placement to raise up to USD $925,000 through the issuance of up to 1,267,123 common share units of the Company at a price of USD $0.73 per unit (the "Offering"). Each Unit will comprise one common share and one common share purchase warrant (a "Warrant"). Each Warrant will entitle the holder, on exercise, to purchase one additional common share in the capital of the Company, at a price of USD $1.20 per Warrant until the close of business on the day which is 60 months from the Closing Date, provided, however, that if the closing price of the common shares on the Nasdaq is greater than USD $2.00 for 10 or more consecutive trading days, the Warrants will be accelerated and the Warrants will expire on the 30th business day following the date of such notice.

TSXV:XRTX

XRTX

XORTX Therapeutics Announces Non-Brokered Private Placement To Raise Up To $925K Through Issuance Of Up To 1.27M Common Share Units At $0.73/Unit

Needham analyst Bernie McTernan reiterates AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on AppLovinto Hold

Rosenblatt analyst Kevin Cassidy maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and raises the price target from $172 to $200.

Rosenblatt Maintains Buy on Micron Technology, Raises Price Target to $200

CRISPR Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced updates across its in vivo cardiovascular disease programs. These include new data for CTX310&#x2122;, targeting ANGPTL3, as well as continued progress on CTX320&#x2122;, targeting the LPA gene, and CTX340&#x2122;, targeting the AGT gene.
"CRISPR Therapeutics remains focused on executing against our strategic priorities and advancing our portfolio of innovative therapies," said&nbsp;Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of&nbsp;CRISPR Therapeutics. "The additional data from our ongoing Phase 1 clinical trial for CTX310 reinforces the potential of our platform to transform the treatment of serious cardiovascular diseases. We are progressing with our dose-finding study and expect to share complete data at a medical meeting in the second half of this year. For CTX320, we are continuing our dose-finding study and anticipate sharing data in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) treatment landscape."
CTX310, targeting ANGPTL3
<ul>
<li>CTX310 targets&nbsp;ANGPTL3, a gene that encodes for key protein involved in the regulation of low-density lipoprotein (LDL) and triglyceride (TG) levels – both of which are recognized risk factors for atherosclerotic heart disease (ASCVD). Loss-of-function mutations in ANGPTL3 are associated with significantly reduced levels of LDL and TGs, as well as reduced risk of ASCVD, without known adverse health effects. More than 40 million patients in the U.S. alone are affected by elevated LDL, severely elevated TG or both – representing a significant unmet need and a large addressable population. CTX310 is initially focused on high-risk patients with the greatest unmet medical need and limited effective treatment options.&nbsp;</li>
<li>CTX310 is in an ongoing Phase 1 first-in-human clinical trial targeting ANGPTL3 in four patient groups: homozygous familial hypercholesterolemia (HoFH), severe hypertriglyceridemia (sHTG), heterozygous familial hypercholesterolemia (HeFH), or mixed dyslipidemias (MDL). Eligible participants have levels of TG &gt;300 mg/dL and/or LDL-C &gt;100 mg/dL (or &gt;70 mg/dL for subjects with ASCVD). Both LDL and TG are validated surrogate endpoints accepted by regulatory agencies.</li>
<li>These new results build upon previously disclosed results from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2 [0.3 mg/kg], DL3 [0.6 mg/kg] and DL4 [0.8 mg/kg]) with at least 30 days of follow-up for each participant. As dose-range finding continues, data to date demonstrate peak reductions of up to 82% in TG and LDL reductions of up to 86% at DL4 without any clinically significant changes in liver enzymes and a safety and tolerability profile consistent with previous findings.</li>
<li>The Company anticipates presenting the complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025.</li>
</ul>
CTX320&#x2122;, targeting LPA
<ul>
<li>CTX320 is in an ongoing Phase 1 clinical trial targeting the&nbsp;LPA&nbsp;gene in patients with elevated lipoprotein(a) [Lp(a)], a genetically determined risk factor associated with increased incidence of major adverse cardiovascular events (MACE). Elevated Lp(a) levels affect up to 20% of the global population and remains unaddressed by current therapies.</li>
<li>The Phase 1 trial is enrolling patients and dose-finding is ongoing. An update is now expected in the first half of 2026, reflecting a strategic decision to incorporate emerging insights from the evolving Lp(a) landscape.</li>
</ul>
CTX340, targeting angiotensinogen (AGT)
<ul>
<li>CRISPR Therapeutics is also advancing its preclinical in vivo cardiovascular program CTX340, targeting angiotensinogen (AGT) for the treatment of refractory hypertension. CTX340 is currently progressing through IND/CTA-enabling studies.</li>
</ul>

CRSP

CRISPR Therapeutics Reports Progress on Gene-Based Treatments for Cardiovascular Diseases with New Data on CTX310 and CTX320

SERV

Serve Robotics Expands Autonomous Delivery Service To Atlanta With Uber Eats, Shake Shack, And Local Favorites

Organizations require proactive PQC readiness strategies to safeguard assets, preserve customer trust, and uphold compliance mandates
F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), the global leader in delivering and securing every app and API, is helping customers prepare for the foundational cybersecurity shift presented by quantum computing. New comprehensive post-quantum cryptography (PQC) readiness solutions are seamlessly integrated into the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.f5.com%2Fproducts%2Ff5-application-delivery-and-security-platform&amp;esheet=54282466&amp;newsitemid=20250626252498&amp;lan=en-US&amp;anchor=F5+Application+Delivery+and+Security+Platform&amp;index=1&amp;md5=067e6dbe9e6be9fe40df666102affb22">F5 Application Delivery and Security Platform</a>, equipping organizations with the tools they need to secure applications and APIs while maintaining high performance and scalability.

FFIV

F5 Launches PQC Readiness Solutions To Secure Apps And APIs

LTRX

Lantronix Secures Multi-Year Deal With Tier-1 US Wireless Operator To Digitally Monitor 50,000+ Backup Generators For Enhanced Network Reliability

<a href="https://www.globenewswire.com/Tracker?data=iu-BaN1J6h2DCCdb4JH88Dcdb-bOBYnLmQi2cHJDIttnRAghQgbfFgLzbR2I5gOSCyd1TrijwPxcuGY1SvZhNQ==">GXO Logistics, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>), the world's largest pure-play contract logistics provider, today announced the launch of <a href="https://www.globenewswire.com/Tracker?data=IOMI2bqN1zRScaDUVLy768OpQwv18SMwQgmxVD8G9xtNI4GcR57K8tdgQ-hxjuzeX911XoXdGzzpYiIinQkBcdDMt9XvihPOIWrnJd8-J50=">GXO IQ</a>, the first AI-powered intelligent platform built for the logistics industry by logistics experts. GXO IQ will help businesses navigate the complexity of today's global supply chains by deploying industry-leading AI capabilities that orchestrate more productive, more dynamic logistics operations.
"Today marks a milestone for GXO and a pivotal moment for the industry as we launch GXO IQ, the first-ever AI-powered, cloud native operating system developed specifically for logistics," said Nizar Trigui, Chief Technology Officer of GXO. "There are few environments more dynamic or complex than a modern warehouse. Thousands of micro decisions are made every day in every site. As throughput increases, experts need a system that thinks with them to effectively anticipate, manage and orchestrate operations intelligently. That's exactly why GXO IQ was built - to be the logistics operating system of the future."
Informed by over 20 years of operational data, GXO IQ leverages a suite of proprietary AI algorithms that intelligently orchestrate millions of complex, multi-step actions across inventory distribution and movement, order picking and packing, shipping, and staffing. GXO IQ was designed by logistics experts and leverages a best-in-class technology stack including Google Cloud's Vertex AI and Snowflake Cortex AI. The tool also leverages Google Cloud's API management product Apigee to give customers secure and seamless access to critical warehouse data.&nbsp;&nbsp;
GXO IQ is comprised of four layers that create a seamless, intelligent operating platform:
<ul>
<li>Data Fabric Layer: GXO IQ utilizes GXO's operational expertise from 20 years of deploying supply chain solutions for customers, along with inputs from thousands of frontline operators, and a data lake that utilizes billions of transactions from GXO operations. Every day, over 200 million signals are streamed and organized to form the data fabric of the platform that trains powerful AI algorithms on every aspect of logistics operations.</li>
<li>AI Orchestration Layer: The AI algorithms are continuously running in the background, predicting demand shifts, anticipating inventory risks, proactively initiating inventory movement, and identifying the ideal pick, pack, and ship process of each order - all in real-time.</li>
<li>End-to-End Execution Layer: The execution layer is comprised of a full suite of logistics management capabilities with marketplace integration and value-added micro-services, including order management, warehousing, returns, and transportation. Services are fully integrated into a cohesive end-to-end solution that can be customized to meet the evolving needs of each individual customer using the platform.</li>
<li>Experience Layer: A unique, persona-based interface with a native, interactive AI agent called ‘GIL' provides a single view to see what's important and help manage the entire process, from real-time order fulfilment status to exceptions management to inventory risk alerts. GIL offers interactive insights that identify opportunities, answers questions and translates complexities into executable recommendations.</li>
</ul>

GXO Logistics Launches GXO IQ, an AI-Powered Platform to Transform Global Supply Chains

Keybanc analyst Jeffrey Hammond upgrades Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) from Sector Weight to Overweight and maintains the price target from $40 to $40.

Upgrades

HLIO

Keybanc Upgrades Helios Technologies to Overweight, Maintains Price Target to $40

KalVista Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has granted Pendopharm, a division of Pharmascience Inc., the exclusive rights to manage the regulatory approval process and commercialization of sebetralstat in Canada. Sebetralstat is an investigational, oral on-demand treatment for hereditary angioedema (HAE).
"We look forward to collaborating with Pendopharm, whose deep knowledge of the Canadian market and proven track record make them a strong partner as we work to bring sebetralstat to people living with HAE," said Ben Palleiko, CEO of KalVista. "This partnership supports our broader goal of making sebetralstat available globally, as the first and only oral on-demand treatment that has the potential to transform HAE care."
Financial terms of the agreement are not being disclosed.

KALV

KalVista Partners with Pendopharm to Bring Sebetralstat to Canada for Hereditary Angioedema Treatment

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks
Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis in up to 59.1% of participants in an ITT analysis
Fibrosis improvement without worsening of MASH in up to 34.5% of participants in an ITT analysis
Supplemental AI-based analysis demonstrated statistically significant reductions in liver fibrosis at 24 weeks
Weight loss of up to 6.2% at 24 weeks with no plateauing
Potentially best-in-class tolerability, with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants
Conference call to be held on June 26, 2025 at 8:30 am ET
GAITHERSBURG, Md., June 26, 2025 (GLOBE NEWSWIRE) -- &nbsp;<a href="https://www.globenewswire.com/Tracker?data=YOr6zKCgGqQv3F1roOZpxCdTUklm3pOuPVaxhGdxtVG3jSUzpwhMZKmQoXcfK34GebAUEtaHt8auaaRaQOTAqw==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced positive topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
The Phase 2b trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive either weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses or placebo for 24 weeks. Treatment discontinuation rates were low, with only 9% of participants prematurely discontinuing treatment. In an intent-to-treat (ITT) analysis, in which participants with missing biopsies were considered non-responders, the proportions of participants achieving MASH resolution without worsening of fibrosis at 24 weeks were 59.1% and 52.1% for pemvidutide 1.2 mg and 1.8 mg, respectively versus 19.1% for placebo (p&lt; 0.0001 both doses). The effects on fibrosis improvement without worsening of MASH in an ITT analysis were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant). A supplemental AI-based analysis demonstrated statistically significant reductions in fibrosis, including 30.6% of participants receiving pemvidutide 1.8 mg achieving a 60% or more reduction in fibrosis compared to 8.2% receiving placebo (p&lt; 0.001). Statistically significant changes in well-established non-invasive tests (NITs) of fibrosis, including Enhanced Liver Fibrosis score (ELF) and Vibration-Controlled Transient Elastography (VCTE) were also observed compared with placebo at both doses. Together, these data suggest strong evidence of anti-fibrotic activity of pemvidutide in the MASH population. At 24 weeks, mean weight loss in pemvidutide-treated participants was 5.0% and 6.2% at the 1.2 mg and 1.8 mg doses, respectively, versus 1.0% in the placebo arm (p&lt; 0.001, both doses). Pemvidutide also demonstrated favorable safety and tolerability, with 0.0% and 1.2% adverse events (AE) related discontinuations in the pemvidutide 1.2 mg and 1.8 mg groups versus 2.4% in the placebo group, and there were no serious adverse events (SAEs) related to study medication.

Altimmune Announces Topline Results From IMPACT Phase 2b Trial Of Pemvidutide In MASH; Trial Meets "Primary Endpoint With Statistically Significant MASH Resolution Without Worsening Of Fibrosis In Up To 59.1% Of Participants In ITT Analysis"

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results.

PTGX

Protagonist Therapeutics to Reveal Oral Obesity Drug Development Candidate and Study Results in Upcoming Call

Earnings

Walgreens Boots Alliance Q3 2025 Adj. EPS $0.38 Beats $0.34 Estimate, Sales $38.99B Beat $36.84B Estimate

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced its collaboration with NVIDIA as part of the Automatica 2025 robotics and automation showcase. The collaboration highlights how Cyngn is leveraging the NVIDIA Isaac robotics platform to power next-generation autonomous vehicle solutions for industrial applications.
&nbsp;
As featured in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457472-1&amp;h=3858890335&amp;u=https%3A%2F%2Fblogs.nvidia.com%2Fblog%2Fautomatica-robotics-2025%2F&amp;a=NVIDIA%27s+recent+blog+post">NVIDIA's recent blog post</a>, Cyngn was selected among a handful of robotics innovators using NVIDIA Isaac technologies to accelerate safe, scalable autonomy across dynamic, real-world environments. Automatica 2025, the world's leading trade fair for smart automation and robotics, provides a global stage for demonstrating how AI-powered solutions are transforming manufacturing and logistics.
Cyngn's autonomous industrial vehicles, built on NVIDIA Isaac and powered by Cyngn's proprietary DriveMod software, are currently operating in commercial environments to reduce labor costs, increase throughput, and improve safety.

NVDA

Cyngn Partners with NVIDIA to Showcase Autonomous Industrial Vehicles at Automatica 2025

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Bit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) with a Buy and maintains $7 price target.

BTBT

HC Wainwright & Co. Reiterates Buy on Bit Digital, Maintains $7 Price Target

PolicyNote's Ease of Use and Quick Time-to-Value Enable Worldwide Scale
Potential Stablecoin Integration Could Further Facilitate International Expansion
FiscalNote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>), a leading AI-driven policy and regulatory intelligence company, today announced that PolicyNote, its next-generation flagship platform, now surpasses the legacy FiscalNote platform in daily active users, a key milestone in customer engagement and product adoption. The rapid growth is fueled by PolicyNote's intuitive design and quick time-to-value, enabling customers to achieve results with minimal friction. As FiscalNote continues to enhance PolicyNote, it expects to unlock incremental long-term international growth by enabling global organizations to discover, provision, and realize value from the platform without the need for significant support. To facilitate this expansion and streamline cross-border transactions, the Company is evaluating the use of stablecoins as a payment option for international customers.

Comments

Slide Insurance Holdings

Slide Insurance Holdings (SLDE) オプション

Slide Insurance Holdings (NASDAQ:SLDE) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル